FC 013LUMASIRAN DEMONSTRATED COMPARABLE OXALATE REDUCTION AND SAFETY IN CHILDREN AND ADULTS WITH PRIMARY HYPEROXALURIA TYPE 1
Hadas Shasha‐Lavsky(Université Claude Bernard Lyon 1), Yaacov Frishberg(Shaare Zedek Medical Center), John M. Gansner(Brigham and Women's Hospital), John C. Lieske(Mayo Clinic), Sander F. Garrelfs(Emma Kinderziekenhuis), Taylor Ngo(Boehringer Ingelheim (Germany)), Nune Makarova(Alnylam Pharmaceuticals (United States)), Tracy L. McGregor(Université Claude Bernard Lyon 1), David J. Sas(Mayo Clinic)
Cited by 0
Related Papers
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
|New England Journal of Medicine|2021|505
Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach
|Kidney International|2013|350
ARHGDIA mutations cause nephrotic syndrome via defective RHO GTPase signaling
|Journal of Clinical Investigation|2013|237
Development and evaluation of deep learning–based segmentation of histologic structures in the kidney cortex with multiple histologic stains
|Kidney International|2020|194
An eQTL Landscape of Kidney Tissue in Human Nephrotic Syndrome
|The American Journal of Human Genetics|2018|184